Glucuronidase deconjugation in inflammation

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• Inflammation involves complex biochemical processes.
• Glucuronidation is a key metabolic pathway for drug and xenobiotic elimination.
• Beta-glucuronidase plays a role in deglucuronidation.

Purpose of the Study:

• To investigate the role of beta-glucuronidase released from human neutrophils in inflammation.
• To determine if beta-glucuronidase can convert glucuronides to free parent compounds at inflammatory sites.
• To assess the impact of inflammation on beta-glucuronidase activity and glucuronide metabolism.

Main Methods:

• Assaying beta-glucuronidase activity using 4-methylumbelliferyl-glucuronide.
• Quantifying released 4-methylumbelliferone using a microplate fluorometer.
• Analyzing deglucuronidation of luteolin monoglucuronide via high-performance liquid chromatography (HPLC).
• Measuring inflammation markers (TNF-α, ICAM-1) and beta-glucuronidase activity in LPS-treated mice.

Main Results:

• Beta-glucuronidase activity increased in mouse plasma after lipopolysaccharide (LPS) injection, correlating with inflammation markers.
• Human neutrophils stimulated in vitro released significant beta-glucuronidase activity.
• Supernatants from stimulated neutrophils hydrolyzed luteolin monoglucuronide to free luteolin.
• LPS treatment in rats reduced luteolin monoglucuronide levels and increased the ratio of free luteolin to its glucuronide.

Conclusions:

• Neutrophils and other cells at inflammatory sites can release active beta-glucuronidase.
• This released enzyme can hydrolyze glucuronide conjugates, potentially increasing the bioavailability of parent compounds.
• The findings suggest a significant role for beta-glucuronidase in modulating drug and metabolite pharmacokinetics during inflammation.